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Abstract
Background—The recommended screening interval when using the Papanicolaou (Pap) and 
human papillomavirus (HPV) test (co-testing) is 5 years. However because providers are reluctant 
to extend the screening interval, we launched a study to identify barriers to appropriate use of the 
co-test and to implement an educational intervention to promote evidence-based screening 
practices. This article provides an overview of the study including the multi-component 
intervention and participant demographics.
Methods—The study was conducted in 15 clinics associated with 6 Federally Qualified Health 
Centers (FQHCs) in Illinois. Each clinic received HPV tests to administer with routine Pap tests 
among enrolled patients (n = 2,246) and was assigned to a study arm: intervention arm (n = 7) 
received a multi-component educational intervention (small media, academic detailing, and 
website) for providers and printed educational materials for patients, and control arm (n = 8) 
received printed copies of general guidelines. Clinic coordinators (n = 15), providers (n = 98), and 
patients (n = 984) completed baseline surveys to assess screening practices.
Results—Providers reported an average age of 41.3 years and were predominately female, non-
Hispanic, and white. Patients reported an average age of 45.0 years and nearly two-thirds were 
Hispanic or black. Of the 2,246 patients, 89% had a normal co-test. Lessons learned from the 
study included the importance of buy-in at a high level in the organization, a champion provider, 
and a clinical coordinator devoted to the study.
© Mary Ann Liebert, Inc.
Address correspondence to: Vicki B. Benard, PhD Division of Cancer Prevention and Control Centers for Disease Control and 
Prevention 4770 Buford Hwy., Northeast MS K-55 Atlanta, GA 30341 vdb9@cdc.gov. 
Author Disclosure Statement
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention. This manuscript was written in the course of employment by the United States Government under 
a contract with Battelle (200-2002-00573, Task Order No. 0006) and it is not subject to copyright in the United States.
No competing financial interests exist.
HHS Public Access
Author manuscript
J Womens Health (Larchmt). Author manuscript; available in PMC 2015 April 06.
Published in final edited form as:













Conclusion—Materials from this study can be adapted to educate providers and patients on 
appropriate use of the co-test and encourage extended screening intervals as a safe and effective 
practice.
Introduction
Based on the central role that persistent carcinogenic human papillomavirus (HPV) plays in 
the development of cervical cancer, HPV testing has been added to cervical cancer screening 
practices. HPV testing with the Papanicolaou (Pap) test (called co-testing) for women age 
30–65 years is a recommended option for cervical cancer screening by all national 
organizations.1–4 From 2003 to 2012, most guidelines recommended extending the 
screening interval to 3 years for women with negative co-test results (normal Pap and 
negative HPV) because of the low risk of cervical precancer and cancer. In 2012, guidelines 
were revised to recommend extending the interval to 5 years for women age 30–65 years. 
Cost-effectiveness studies have demonstrated that the increased screening interval for 
women with negative co-tests (estimated to be about 90% of those screened) offsets the 
additional cost of the DNA test.5–7 However, annual screening, regardless of screening 
strategy, remains the common practice throughout the United States and across provider 
specialty.8–10 Studies in managed care settings examining the acceptability of the co-test 
strategy for screening found that both providers and women were amenable to the longer 
intervals once they understood the role of HPV in the development of cervical cancer.11,12
To date, no studies have examined provider and patient acceptance of co-testing with longer 
screening intervals in a low income population. The Centers for Disease Control and 
Prevention (CDC) launched the CDC Cervical Cancer (Cx3) Study—a multi-component 
educational intervention to identify facilitators and barriers to guideline-consistent use of the 
co-test in an underserved population. The primary objective of this study was to determine 
whether an educational intervention would lead to increased willingness of providers and 
patients to extend the cervical cancer screening interval for women with negative co-tests 
and decrease cervical cancer screening visits to clinic sites for average risk women. This is 
contrary to most social marketing campaigns and patient education interventions that 
advocate annual Pap tests.
The purpose of this article is to give a detailed overview of the Cx3 Study and lessons 
learned once implemented in the field.
Methods
Study participants
The Cx3 Study selected Federally Qualified Health Centers (FQHCs) because the client base 
is predominately low income and under- or uninsured. Recruitment of FQHCs occurred 
through the CDC's National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP).13 The Illinois program was chosen based on high Pap volume, high follow-up 
rate, and elevated cervical cancer incidence rates in their state compared with national rates. 
FQHCs that partnered with the Illinois Breast and Cervical Cancer Early Detection Program 
and reported high volume Pap testing with a multispecialty team were chosen for the study. 
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All providers within the clinics who were part of the NBCCEDP and routinely performed 
cervical cancer screening were eligible for the study. Women coming into the clinics for 
routine well women exams were eligible if they were between the ages of 30 and 60 years at 
the time of enrollment and scheduled for a regular screening Pap test but were excluded if 
they had an abnormal Pap test in the last year, a history of cervical cancer, or a 
hysterectomy. Women did not have to be part of the NBCCEDP to participate in the study. 
The CDC Institutional Review Board approved this study.
Study design
Six FQHCs with 15 individual clinics were enrolled in the study by August 2009. Each 
clinic was assigned to one of two study arms: intervention (n = 7) or control (n = 8). The 
intervention and control arms were matched on clinic attributes including racial/ethnic 
characteristics of the patient population, provider specialty, and patient volume. Clinics in 
both groups received free HPV tests and hard copies of clinical practice guidelines. 
Additionally, clinics in the intervention group received a multi-component educational 
program, including provider and patient education materials designed for this project. 
Ninety-eight providers were enrolled in the study from August 2009 through March 2010 
and 2,246 women were enrolled in the study from October 2009 through May 2011.
At the time of the woman's examination, two samples of exfoliated cervical cells were 
collected. The first used the clinic's routine sampling method for cytology diagnosis. The 
second sample was collected using the HC cervical sampler (Qiagen, Inc.) and sent to the 
CDC HPV lab for the Hybrid Capture 2 High Risk HPV DNA test (Qaigen, Inc.) The HPV 
test results were sent to the provider who was responsible for informing patients of the 
results following their standard reporting procedures.
Intervention
Educational materials for the intervention arm were developed based on qualitative data 
collected from 6 providers in Illinois who participated in a 2-hour face-to-face interview to 
discuss screening practices and barriers to guideline-consistent intervals. A recurring 
message in the interviews was the reluctance of the woman to return for her well-woman 
exam and other screening tests if she was not coming in for an annual Pap test. Therefore, 
our messages included the importance of other medical procedures that were not linked to 
the Pap test.
Provider Intervention—Providers in the intervention arm were offered three types of 
intervention over 9-months.
• Grand Rounds continuing medical education (CME) events were held in August 
2009 at all intervention arm clinics and led by leaders in women's health. 
Discussion included the screening guidelines that incorporate HPV testing as part 
of the Pap test and the importance of extending the screening interval from a risk 
and cost perspective.
• Four, one-hour academic detailing sessions were offered in September 2009 
through June 2010. The four modules were presented at all clinics in the 
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intervention arm and providers received CME credit for their participation in the 
trainings. The content and tools distributed at the four academic detailing sessions 
are summarized in Table 1.
• Providers were given access to a password-protected website that contained a 
repository of CME programs, CDC-developed podcasts on the recommended 
intervals for cervical cancer screening, and relevant peer-reviewed articles.
Patient intervention—A patient brochure and bookmark emphasizing the co-test and the 
extended screening interval were developed for the study in both English and Spanish.14 The 
22-page educational brochure was written at a sixth grade reading level.15 These materials 
were distributed to patients in the intervention group after they completed the baseline 
survey.
Data collection
Enrolled patients consented to have their medical and billing records accessed by study 
personnel for a period of 40 months following the date of study enrollment (Table 2). The 
main outcomes were to determine (1) whether a woman who had a normal Pap test and a 
negative HPV test returned for her routine well woman exam, and (2) whether this exam 
included screening tests according to guidelines. In addition, medical records will be used to 
determine the type of follow-up care received by women with HPV positive test outcomes.
Other study variables were gathered from surveys of clinics, providers, and patients (Table 
2). Clinic coordinators at each of the 15 participating clinics were surveyed three times: (1) 
at baseline to request information about the clinic patient population and practice 
characteristics; (2) monthly for 11 months to request staff time associated with study; and 
(3) at 12 months to assess changes in HPV practice and systems interventions. Coordinators 
at participating clinics distributed baseline surveys along with a $50 cash incentive to 
providers. The surveys assessed knowledge, attitudes, beliefs, and practices regarding 
cervical cancer screening.16 Roland et al. provides greater detail on the baseline survey 
results, we list only a summary of the demographic variables.16 Follow-up surveys at 12 and 
36 months are also planned. A sample of patients (n = 984) were asked to complete a 
baseline survey to assess knowledge, attitudes, beliefs, and behavior regarding cervical 
cancer screening.17 Only a summary of patient demographics are presented in this paper. 
Staff at participating clinics distributed the baseline survey to patients prior to the patient's 
HPV test. Patients were given a $5 cash incentive for participating. The 12-page patient 
survey was written at an eighth-grade level and was self-administered in English and 
Spanish. A 15-month follow-up survey is planned.
Results
Of the 2,246 patients who had both HPV and Pap tests, 2,002 (89.1%) had a normal Pap test 
and a negative HPV test.18 These women will have a chart review at 40 months to determine 
if well-woman exams were performed and what screening tests occurred. The HPV test was 
positive in 162 (7.2%) women. (Data not shown.)
Benard et al. Page 4













At the time of the baseline survey, HPV test use varied among providers at the study clinics. 
Most of the providers were using the HPV test for management after an abnormal Pap test 
(ASC-US) (91%) and fewer were using HPV for co-testing (39%).16 Most of the clinics 
(66%) had at least one provider who could conduct colposcopies on site. In the case of 
abnormal test results, most clinics relied on a combination of systems for follow-up 
including verbal prompts, mail and telephone reminders. Only one clinic did not have any 
reminder system in place. (Data not shown.)
A sample of the provider and patient characteristics are provided in Table 3. The average 
age of the providers was 41.3 years at the time of study initiation. Almost 70% of the 
providers were from the Chicago area. Approximately three-quarters of the providers were 
female and the majority were non-Hispanic (94%). With respect to race, 55% reported that 
they were white, 20% reported that they were black, and 25% reported that they were Asian. 
The average age of the patient sample at the time of recruitment was 45.0 years. Nearly one-
third of the patient sample reported that they were Hispanic, and 26% that they were African 
American. Nearly one-third of those surveyed (31%) were born outside of the U.S, 26% 
were born in Mexico, and 28% reported that they normally speak Spanish in the home.
Lessons learned
By choosing to conduct the study in FQHCs, we were able to operate in a real-world setting 
and at the same time observe the nuances associated with conducting this type of research. 
This information is extremely important, as most studies are conducted in a research setting 
with little ability to be transferred to ongoing clinical practice. We learned that it is 
important to get buy-in at a high level in the organization so that when operational changes 
need to be made (for example, sending a reminder letter to a woman with negative tests to 
return in 3 years and not annually as was most of the clinic protocols) it can be disseminated 
efficiently and effectively. It is also important to identify a champion provider who can help 
gain momentum for the study and emphasize the importance of participating. We also 
learned that having a full-time clinical coordinator devoted to the study is key, since adding 
additional responsibilities for office staff who are already overburdened is not the most 
efficient model.
Discussion
This study was developed to identify barriers to appropriate use of the co-test, and to 
implement an educational intervention to promote evidence-based screening practices. This 
article provides a detailed overview of the study including the multi-component intervention 
and brief participant characteristics. Additional information on the lessons learned is also an 
important contribution to the literature in conducting this type of study in the field. The lack 
of a physician recommendation for cancer screenings is one rea son why women report not 
being screened.19 One interventional strategy to disseminate evidence-based, provider-
oriented interventions (provider assessment and feedback and provider reminders)20 is 
academic detailing.21 Multiple studies in the literature have used these techniques to 
improve recruitment for screening but very few interventions have been introduced to 
address how to screen at the appropriate intervals (in this case, to decrease screening when 
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not recommended). This study provided multiple evidence-based strategies to encourage 
providers to follow recommendations, including placing current screening guidelines in 
charts, discussing reimbursement codes, offering current literature on co-testing, and office-
based materials (small media, examples of client reminders, discussions regarding system 
interventions). Additionally, podcasts were developed by professional experts in their 
communities covering recommended follow-up. Despite these efforts, the practice of annual 
screening may be difficult to change even after newer guidelines have recommended less 
frequent screening.
The impetus for this study was to understand the barriers with co-test use and the extension 
of the interval between screenings in the underserved population. To improve cervical 
cancer screening among medically underserved women, Congress authorized the CDC to 
develop the National Breast and Cervical Cancer Early Detection Program (nBCCEDP) in 
1991.13 The NBCCEDP is a comprehensive public health program that helps low-income, 
under- and un-insured women gain access to breast and cervical screening services. Before 
the 2012 revision to the USPSTF screening guidelines, 22 the NBCCEDP reimbursed for the 
HPV test for management of cervical cancer, but not as a co-test23. Therefore, this pilot 
study was also designed to provide feedback to the national program on facilitators and 
barriers to appropriate use of the co-test including screening intervals. This information is 
now even more useful, as the NBCCEDP began reimbursing for the co-test in July 2012 and 
will be using the outcomes of this study and the materials developed to help providers and 
patients adopt new recommendations.
This study had many strengths including enrolling over 2,000 low-income, un- and under- 
insured patients in the setting of FQHCs across a diverse population of urban and rural 
clinics in Illinois. Research among FQHC patients and providers allows for understanding 
the access and barriers to care among the underserved. These facilities and their staff 
provide care regardless of a person's insurance status, income, or ability to pay, and they are 
a large, essential component of the U.S. healthcare safety net for people who otherwise have 
limited options to access essential care.24 Additionally, the multi-level assessment of the 
clinics, providers and patients provides details to understand how practices, attitudes and 
beliefs will change over time including the increase in the 3- to 5-year screening interval. 
This study also has the capacity to follow women with positive test results since they will 
have medical chart review through the 40 months. Additionally, the educational intervention 
that was developed gives the rationale for using all of the strategies for cervical cancer 
screening including longer intervals regardless of the method to screen.
As a demonstration study in one state, our results may not be generalizable to all. However, 
when we examined the racial and ethnic distribution of this study population in Illinois, it 
was very similar to the NBCCEDP racial and ethnic distribution. Since most of the clinics in 
our study did not have research experience, we faced challenges such as longer-than-
expected patient enrollment, no data collection on the women who refused to participate 
(which does not allow us to calculate a response rate for patients), and limited staff time at 
one of the health centers to conduct the survey portion of the study.
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While many studies are aimed at introducing new technology, very few are focused on 
introducing new technology coupled with evidence-based strategies that emphasize less but 
more-efficient screening. When complete, the Cx3 Study will provide a wealth of 
information on current trends in screening and effective approaches for encouraging 
guideline-adherent cervical cancer screening. These findings on practices and attitudes 
regarding HPV testing and screening interval extension are very timely with all national 
organizations recommending co-testing and extended screening intervals. Additionally, the 
management guidelines are being updated with a focus on triaging women with specific 
high-risk HPV types23; thus, as the science advances, conveying this information to 
providers and patients will be essential to encouraging the most effective patient care. The 
information on the harms of over-testing—which may lead to over-diagnosis and 
overtreatment—is only useful to the extent that it is understood and accepted by providers 
and patients. CDC has produced several materials to educate providers and patients on the 
appropriate use of the co-test, and these materials may be adapted over time to meet the 
changing needs of the population and the latest science.
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Table 1
Content of Academic-Detailing Component of the Provider Intervention for the Cx3 Study, 2009-2010
Session title Content Tools distributed
I: Updates and Guidance 1.Cervical cancer and HPV: epidemiology and 
natural history
2.Cervical cancer screening guidelines
3.Resources for additional training
Cervical cancer screening guideline summary sheet, 
ASCCP algorithm booklets, password to website, patient 
brochures, recommended reading (hard-copy articles)
II: Physicians' Perspective 
and Office Management
1.Physician perspective on changes to screening 
guidelines
2.Conversations with patients about HPV and 
cervical cancer
3.Office management and tracking system
ASCCP algorithm wall posters, Cx3 study poster, Qiagen 
HPV materials, billing and reimbursement code sheet, risk 
stratification chart, examples of client reminders, AHRQ 
Your checklist for health brochure
III: Patient Management 
and Guidelines
1.Overview of ASCCP guidelines
2.Algorithms for patient management
3.Algorithms for special populations
ASCCP algorithms, ASCCP online modules (CME), 
example letters to send to patients for follow-up, 
recommended reading
IV. HPV Vaccine 1.HPV vaccine
2.Review of cervical cancer screening guidelines
Web resources from CDC
ASCCP, American Society of Colposcopic and Cervical Pathology; CDC, Centers for Disease Control and Prevention; CME, continuing medical 
education; Cx3, CDC's Cervical Cancer Study; HPV, human papillomavirus.
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Table 2
Schedule and Methods for Measuring Variables in the Cx3 Study, 2009-2014
Schedule
Measures Initiation 12-15 months 36-40 months
Medical chart review – HPV negative 
tests
Completion and measures of a well woman exam 
(including Pap and HPV testing)
X
Medical chart review – HPV positive 
tests
Pap and HPV testing, diagnostic and treatment 
reports
X X







Personal and professional 
characteristics
Race/ethnicity, age, sex, type of provider, clinical 
specialty, number of years providing clinical care
X
Patient characteristics Age and sex of patient population seen by provider X X X
Cervical cancer screening practices Volume of Pap tests performed, management on site, 
type of Pap test, reason for type of Pap test
X X X
Risk assessment management Perceived importance of annual exams, tests 
conducted during annual exam
X X X
HPV test practices Attitudes, beliefs and practice X X X
Screening interval questions Clinical vignettes to determine screening practices; 
attitude, beliefs and practices
X X X
HPV vaccine Recommendations regarding use X
Education/guidelines Guidelines followed for cervical cancer screening 




Sociodemographic characteristics Race/ethnicity, age, marital status, years of 
education, insurance status, country of origin, 
primary language
X X
Cervical cancer screening history Number of visits to that clinic, lifetime number of 
Pap tests, frequency of getting Pap tests, abnormal 
Pap history, recommended Pap interval, previous 
HPV testing and result
X X
Risk factor assessment Age at first intercourse, number of sexual partners, 
STDs, warts, smoking
X X
Knowledge and attitudes about 
cervical cancer screening
Knowledge and source of information regarding HPV 
and Pap tests, level of acceptance for getting an HPV 
test, level of acceptance for a 3-year screening 
interval, perceived barriers to an extended screening 
interval
X X
Cost of health care services Direct and indirect costs associated with visits to the 
study clinic
X
STD, sexually transmitted disease.
*
Staff time was assessed every month to conduct cost of the intervention.
†
Change in HPV test use or systems was assessed on the final survey (12 months).
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Table 3
Personal Characteristics of Providers and Patients Who Completed the Baseline Survey for the Cx3 Study
Providers, 2009-2010 N Percent or mean ± standard deviation
Age
Age at baseline, years 98 41.3 ± 11.4
Location of clinic
Chicago 68 69




Hispanic or Latino origin
Hispanic 6 6
Non-Hispanic 92 94
Race or racial heritage (respondent could check all that apply)
White 51 55
Black or African American 19 20
Asian 23 25
Native Hawaiian/Pacific Islander 1 1
American Indian/Alaska native 1 1
Type of clinician
Physician 65 66
Nurse practitioner 20 20
Certified Nurse Midwife 6 6
Physician's Assistant 7 7
Primary clinical specialty
Family Medicine 35 36
Internal Medicine 8 8
Obstetrics/Gynecology 52 53
Pediatrics 1 1
Number of years providing clinical care
Years at baseline 98 8.8 ± 9.5
Patients, 2009-2011 N Percent or mean ± standard deviation
Age
Age at baseline, years 984 45.0±7.5
Location of clinic
Chicago 566 58
Outside Chicago 418 42
Race/ethnicity
Hispanic 312 32
Non-Hispanic white 384 39
Non-Hispanic Black, African American 254 26
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Patients, 2009-2011 N Percent or mean ± standard deviation
Non-Hispanic other/multiple races 26 3
Marital status
Never married 176 18




Highest level of schooling completed
Elementary school 95 10
Middle school 83 9
High school, no diploma 122 13
High school diploma or GED 217 23
Some college or associate's degree 296 31
Bachelor's degree 89 9
Masters/doctoral degree 44 5
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